Alexza Pharmaceuticals ( ALXA -0.5% ) completes the initial stocking of Adasuve (loxapine) inhalation powder (Staccato loxapine) for the U.S. launch
Alexza Pharmaceuticals ( ALXA -2.6% ) will report Q3 results on November 5 after the close. The conference call will begin at 5:00 m ET. Consensus view is a loss of ($0.77) per share on revenues of $3.2M. Post your comment!
(Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.
Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain
We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third
Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing
We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development
Alexza Pharmaceuticals ALXA announced positive results from its second Phase III trial of its lead antipsychotic drug, AZ-004, for treatment of acute agitation
We're lowering Alexza Pharmaceuticals ' ALXA fair value uncertainty rating. Although we believe the company still represents a very speculative investment, we don't feel